Eric S Daar, MD
Interim Chair, Department of Medicine at Harbor-UCLA Medical Center
Chief, Division of HIV Medicine at Harbor-UCLA Medical Center
Professor of Medicine, David Geffen School of Medicine at UCLA
Management and Immunopathogenesis of HIV infections and its complications
Research DescriptionDr. Daar is an infectious diseases-trained clinician-investigator with nearly 25 years of experience conducting clinical and translational research related to HIV/AIDS. His research focuses on management and therapy for HIV infections, the immunopathogenesis and neuropathogenesis of primary and chronic HIV infection and the long-term complications patients face living with HIV and antiviral drugs. Additionally, he studies the area of HIV testing, linkage and retention of patients into care and prevention strategies as well as the management of HCV infection
Dr. Daar is former chair of the Antiretroviral Strategies Scientific Subcommittee of the AIDS Clinical Trials Group and the NIH Prevention Trials Data Safety Monitoring Board. He also served as a member of the United States Health and Human Services (HHS) Guidelines Panel for Antiretroviral Therapy for Adults and Adolescents from 2007 to 2015.
- MD, 1985, Georgetown University School of Medicine
Recent and/or Significant Publications
- Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES, for the AIDS Clinical Trials Groups Study A5202 Team. Tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine as part of once-daily regimens for initial treatment of HIV-1 infection. N Engl J Med 2009; 361:2230-2240. [PMID: 19952143]
- Rieg G, Butler DM, Smith DM, Daar ES. Seminal plasma HIV RNA in patients with asymptomatic sexually transmitted infections. International J STD & AIDS 2010; 21:207-208. [PMID: 20215629]
- Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC, for the AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a three drug regimen for initial treatment of HIV-1: A randomized, controlled equivalence trial. Ann Intern Med 2011; 154:445-456 [PMID: 21320923].
- McComsey GA, Kitch D, Sax PE, Tierney C, Jahed NE, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Daar ES. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr 2014; 65:167-174 [PMID 24121755].